[Federal Register Volume 66, Number 12 (Thursday, January 18, 2001)]
[Notices]
[Pages 4847-4848]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-1464]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Orally Active Derivatives 
of 1,3,5(10)-Estratriene

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION:  Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license worldwide to practice the invention embodied in: 
U.S. Patent Application Series No. 08/122,853, filed September 17, 
1993, issuing as U.S. Patent 5,554,603 on September 10, 1996 entitled, 
``Orally Active Derivatives of 1,3,5(10)-Estratriene'' to the R.W. 
Johnson Pharmaceutical Research Institute, a corporation of Delaware, 
having a place of business in Raritan, New Jersey. The patent rights in 
this invention have been assigned to the

[[Page 4848]]

United States of America, as represented by the Department of Health 
and Human Services.

DATES: Only written comments and/or application for a license which are 
received by the NIH Office of Technology Transfer on or before March 
19, 2001 will be considered.

ADDRESSES: Requests for a copy of the patent applications, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Dennis H. Penn, Pharm.D., Technology Licensing 
Specialist, Office of Technology Transfer, National Institutes of 
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; 
Telephone: (301) 496-7056, ext. 211; Facsimile: (301) 402-0220.

SUPPLEMENTARY INFORMATION: In an effort to develop an efficacious 
treatment for human reproductive disorders this invention describes 
orally active derivatives of 1,3,5(10)-estratriene. This compound may 
have utility as a contraceptive and as an estrogen replacement for the 
treatment and prevention of postmenopausal conditions.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless, within 60 days 
from the date of this published Notice, NIH received written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    The field of use may be limited to the use of the invention for the 
development of pharmaceutical compounds for use as a contraceptive and 
for treatment and prevention of postmenopausal conditions.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: January 8, 2001.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 01-1464 Filed 1-17-01; 8:45 am]
BILLING CODE 4140-01-M